Dermatology News

Dermatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Korting HC et al. – The most commonly used and most established therapeutic regimens are topical metronidazole and topical azelaic acid as well as oral doxycycline. Conventionally, 100–200 mg per day have been used. Today also a controlled release formulation is available, delivering 40 mg per day using non–antibiotic, anti–inflammatory activities of the drug. Anti–inflammatory dose doxycycline in particular allows for a safe and effective short– and long–term therapy of rosacea. Topical metronidazole and topical azelaic acid also appear to be safe and effective for short–term use. There are indications that a combined therapy of anti–inflammatory dose doxycycline and topical metronidazole could possibly have synergy effects.

Today in Clinical Pharmacology...keeping you current

Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults
Journal of the European Academy of Dermatology and Venereology, 12/17/09

Multiple epidermal cysts occcurring in a tattoo
Singapore Medical Journal, 12/17/09

Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infection: a meta-analysis
Current Medical Research and Opinion, 12/17/09

Today in Dermatopathology...keeping you current

Use of a novel autologous cell-harvesting device to promote epithelialization and enhance appropriate pigmentation in scar reconstruction
Clinical and Experimental Dermatology, 12/17/09

Multiple epidermal cysts occcurring in a tattoo
Singapore Medical Journal, 12/17/09

The Influence of Environmental Temperature on the Response of the Skin to Local Pressure: The Impact of Aging and Diabetes
Diabetes Technology & Therapeutics, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address